BRIEF—Bora Pharma links with Bright Future on PD drug

Taiwan drug maker Bora Pharmaceuticals has signed a distribution deal with its Hong Kong-based counterpart Bright Future to supply the extended release (ER) combo drug Numient (carbidopa/levodopa) to treat Parkinson's disease in China, including Hong Kong and Macau.

Numient, sold in the USA under the brand Rytary, is supplied by the US company Amneal.

Bora is Amneal's contracted manufacturer for Numient, and holds the commercial rights to the drug in many other Asian countries including Japan, South Korea and Thailand.

The company said Bright Future has a well-established distribution network in China that serves 18,000 hospitals nationwide.

China currently does not have an ER drug to treat PD, but it granted local pharma firm Hengrui approval to start clinical studies for its ER combo candidate HRG2010 in September 2021.